Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in OSA and Obesity
NCT05412004Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of tirzepatide in obstructive sleep apnea (OSA), obesity, sponsored by Eli Lilly and Company. Started Jun 2022; status: completed.
02
Drugs
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT05412004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412004.